Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (91-100 of 188) with videos related to

Pageof 19
Sort By:
British Journal of Haematology|February 13, 2010
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcomeMarie-Christiane Vekemans, Heidi Lemmens, Michel Delforge, et al.
Acta Obstetricia Et Gynecologica Scandinavica|September 18, 2010
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical studyKristel Van Calsteren, René Verbesselt, Nelleke Ottevanger, et al.
Stem Cells (Dayton, Ohio)|March 25, 2011
Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditionsValerie D Roobrouck, Carlos Clavel, Sandra A Jacobs, et al.
Haematologica|February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myelomaMaria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
Frontiers in Oncology|December 16, 2022
What matters most to patients with multiple myeloma? A Pan-European patient preference studyRosanne Janssens, Tamika Lang, Ana Vallejo, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
British Journal of Haematology|July 17, 2009
Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survivalTheo de Witte, Ronald Brand, Anja van Biezen, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Haematologica|October 17, 2024
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United StatesMalin Hultcrantz, David Kleinman, Ravi Vij, et al.
Pageof 19

Showing results (91-100 of 188) with videos related to

Sort By:
Pageof 19
British Journal of Haematology|February 13, 2010
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcomeMarie-Christiane Vekemans, Heidi Lemmens, Michel Delforge, et al.
Acta Obstetricia Et Gynecologica Scandinavica|September 18, 2010
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical studyKristel Van Calsteren, René Verbesselt, Nelleke Ottevanger, et al.
Stem Cells (Dayton, Ohio)|March 25, 2011
Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditionsValerie D Roobrouck, Carlos Clavel, Sandra A Jacobs, et al.
Haematologica|February 22, 2024
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myelomaMaria Victoria Mateos, Katja Weisel, Evangelos Terpos, et al.
Frontiers in Oncology|December 16, 2022
What matters most to patients with multiple myeloma? A Pan-European patient preference studyRosanne Janssens, Tamika Lang, Ana Vallejo, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
British Journal of Haematology|July 17, 2009
Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survivalTheo de Witte, Ronald Brand, Anja van Biezen, et al.
Hemasphere|February 8, 2021
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-upMeletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Haematologica|October 17, 2024
Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United StatesMalin Hultcrantz, David Kleinman, Ravi Vij, et al.
Pageof 19